In a 90 minute meeting with HIV advocates and implementers today, Ann Gavaghan spent almost as much time explaining what PEPFAR’s new five-year strategy does not mean as what it does mean. The term “increased efficiencies” is not some code for budget cuts, Gavaghan promised, but rather a mandate to maximize the impact of PEPFAR […]
HIV
The following is a guest post by Mitchell Warren of AVAC This year’s annual HIV Vaccine Awareness Day arrives Saturday at a promising and also perilous […]
Tuberculosis
In sub-Saharan Africa where the odds of dying within a year of starting treatment for HIV can still hover close to one-in-10, diagnosing and treating TB […]
Research & Development
A randomized, multi-country clinical trial testing a regimen for treating drug-resistant tuberculosis in less than a year against the up to two-year regimen recommended by the […]
Policy
The following is a guest post by Heather B. Davis, MPH, and Emily A. Bobrow, PhD, MPH, of MEASURE Evaluation Who has a strategic interest in […]